RecruitingNCT06491056
Prospective Asian Multicenter Prostate Cancer Focal Therapy Study (ProAMFocal)
Prospective Multicenter Asian Observational Study of Oncological and Functional Outcomes After Focal Therapy of Prostate Cancer
Sponsor
Singapore General Hospital
Enrollment
500 participants
Start Date
May 6, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This is a multicenter observational study of patients undergoing focal therapy for prostate cancer in Asia
Eligibility
Sex: MALEMin Age: 40 YearsMax Age: 85 Years
Inclusion Criteria6
- Prostate Adenocarcinoma
- Maximum Gleason score 4+4
- Maximum cancer volume 1.5 ml (up to 2 lesions) or 3 ml (single lesion)
- Maximum Prostate Specific Antigen (PSA) level 15 ng/dl
- Maximum clinical stage T2c
- American Society of Anesthesiologist Criteria 2 or less
Exclusion Criteria1
- Extra-prostatic Extension on multi parametric magnetic resonance imaging (mpMRI); capsular contact is permitted
Interventions
DEVICEFocal Therapy for Prostate Cancer
Ablation of \<75% of the prostate gland for limited volume prostate cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06491056
Related Trials
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
NCT070271241 location
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location